

PD52 The Role Of Public Consultation In CONITEC Recommendations Between 2012 And 2020: An Introductory Analysis

Andrea Brigida Souza (andrea.brigida@saude.gov.br),
Clarice Portugal, Adriana Prates, Andrija Almeida,
Bruna Cabral de Pina Viana, Luiza Losco and Vania Canuto

Introduction. Public consultation is a strategy for patient and public involvement (PPI) assured by the National Committee for Health Technology Incorporation in Brazilian Public Health System (CONITEC)'s normative framework. It aims to obtain society's views on the matters under evaluation. It is made available after CONITEC issues an initial recommendation, which will be reviewed in light of society contributions. This paper examines the cases where the final recommendations differed from the initial ones in technology assessments carried out between 2012 and 2020, taking into account the arguments used by the CONITEC Plenary to support the modification. **Methods.** From a total of 361 public consultations referring to the assessment of health technologies carried out by CONITEC between 2012 and 2020, 40 final reports of health technology assessment (HTA) processes that had changes from the initial to the final recommendation were examined. Then, analytical categories were built so that justifications for the change were investigated and the interpretations produced. The empirical approach excluded public consultations regarding clinical protocols and therapeutic guidelines. **Results.** It was observed that, in 39 cases, the change occurred from an unfavorable position to a favorable position for the technology incorporation. The main reasons for changing the plenary's decision were proposals to renegotiate the prices of technologies (that generate changes in the results of economic evaluation and budget impact analysis), the receipt of new evidence and experience, and opinion arguments sent mainly by health professionals. **Conclusions.** The analyzed data has shown that the changes in recommendations are mostly based on the content of contributions which led to changes in the assessment of clinical evidence, economic evaluation and budget impact. Thus, it appears that public consultation has been consolidated as a relevant instrument to inform the deliberative process in HTA in Brazilian Public Health System.

PD53 Improving Patient Involvement In The National Institute For Health And Care Excellence's Appeals Process

Heidi Livingstone (heidi.livingstone@nice.org.uk) and
Maria Pitan

Introduction. Involving patients in the health technology assessment (HTA) lifecycle is a core principle at the National Institute for Health and Care Excellence (NICE) that helps build public confidence in healthcare decision-making. The last stage in this lifecycle is an appeal whereby stakeholders, including patient organizations, can appeal against the HTA committee's decision based on two specific grounds: (i) the committee has failed to act fairly or NICE has exceeded its powers; and (ii) the recommendation is unreasonable considering the evidence submitted to NICE. Improving patient involvement in the appeals process was identified as a key area from consultative work undertaken with patient organizations in 2019.

Methods. In September 2020, surveys were sent to patient organizations for their feedback. The organizations received a survey tailored to their circumstances in relation to the following four outcomes.

- (i) An appeal was lodged that: (a) resulted in an appeal hearing; or (b) did not result in an appeal hearing.
- (ii) An appeal was not lodged but the organization had received: (a) negative guidance; or (b) 'optimized' guidance.

Results. Sixteen responses were received across the four surveys. The key findings in priority order were as follows.

- (i) The legalist nature of appeal hearings is off-putting.
- (ii) The online appeals guide and template letter are not easy to use.
- (iii) Organizations would like more information on appeal hearings and timelines.
- (iv) Organizations would like patient-friendly materials and training on par with the support they receive for other HTA participation.

Conclusions. As a result of these findings, we are iteratively developing materials to support patient organizations, including:

- a glossary;
- a redesigned appeals web page with clearer timelines and a template letter;
- a 'Frequently Asked Questions' document specifically for patient organizations; and
- a video podcast from a lay appeals panel Chair explaining appeals in a patient-friendly way.

We are also including a section on appeals in our introductory training for all patient organizations participating in medicines HTAs.

PD54 Burden Of Disease And Risk Factors Among Children Under 5 Years In China From 1990 To 2019

Fuming Li, Shiyu Xie, Zhixin Jiang, Shiyi Bao,
Yanfeng Ren and Yingyao Chen (yychen@shmu.edu.cn)

Introduction. According to the Healthy China 2030 Plan, children under 5 years is the main focus group to achieve universal health and sustainable development of China. To identify the major threats to